## Catherine M Owczarek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8892937/publications.pdf

Version: 2024-02-01

1478280 1372474 125 10 10 6 citations h-index g-index papers 11 11 11 236 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common $\hat{l}^2$ chain of the IL-3, GM-CSF and IL-5 receptors. MAbs, 2016, 8, 436-453.	2.6	38
2	Role of the $\hat{l}^2$ Common ( $\hat{l}^2$ c) Family of Cytokines in Health and Disease. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028514.	2.3	28
3	Mining the Plasma Cell Transcriptome for Novel Cell Surface Proteins. International Journal of Molecular Sciences, 2018, 19, 2161.	1.8	17
4	Antiâ€Î² <sub>c</sub> mAb CSL311 inhibits human nasal polyp pathophysiology in a humanized mouse xenograft model. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 475-478.	2.7	10
5	Blocking the human common beta subunit of the GM-CSF, IL-5 and IL-3 receptors markedly reduces hyperinflammation in ARDS models. Cell Death and Disease, 2022, 13, 137.	2.7	9
6	Crystallization and preliminary X-ray diffraction analysis of the interleukin-3 alpha receptor bound to the Fab fragment of antibody CSL362. Acta Crystallographica Section F, Structural Biology Communications, 2014, 70, 358-361.	0.4	8
7	Glycoproteomic measurement of site-specific polysialylation. Analytical Biochemistry, 2020, 596, 113625.	1.1	5
8	Targeting the human $\hat{l}^2$ sub>c receptor inhibits inflammatory myeloid cells and lung injury caused by acute cigarette smoke exposure. Respirology, 2022, 27, 617-629.	1.3	5
9	Targeting the Human $\hat{I}^2$ c Receptor Inhibits Contact Dermatitis in a Transgenic Mouse Model. Journal of Investigative Dermatology, 2022, 142, 1103-1113.e11.	0.3	4
10	Identification of potent antagonist antibodies against mouse IL- $13R\hat{l}\pm1$ using novel bioassays. Journal of Immunological Methods, 2014, 407, 48-57.	0.6	1